36F79720D0016-36C25024A0008
This Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration to Polymedco LLC, doing business as Polymedco Cancer Diagnostic Products, provides a multi-year contract vehicle for the VA to acquire a range of cancer screening, diagnostic, and treatment-related goods and services.
The BPA, which falls under Polymedco's parent General Services Administration Federal Supply Schedule contract for Critical Analyzers, Laboratory, enables the VA's Veterans Integrated Service Network (VISN) 10 to efficiently procure fit testing services, fecal immunochemical tests, colorectal analyzers, immunochemical fecal occult blood testing, and associated supplies and reagents. Through task orders and BPA calls issued against this single-award IDV, Polymedco has received contract values ranging from thousands to over $1.4 million to deliver the requested products and services nationwide to support the VA's healthcare programs.
Polymedco LLC
$225.4k 1/1/24 12/31/28 12/17/24 36F79720D0016-36C24821A0028
This federal contract IDV award is a Blanket Purchase Agreement (BPA) between the Department of Veterans Affairs (VA) Veterans Health Administration and Polymedco LLC, a for-profit organization doing business as Polymedco Cancer Diagnostic Products. The BPA, awarded under Polymedco's General Services Administration (GSA) Federal Supply Schedule contract for Critical Analyzers, Laboratory, establishes a standardized multi-year vehicle for the VA to efficiently acquire a range of cancer screening, diagnostic, and treatment-related goods and services.
Specifically, the BPA and associated task orders enable the VA to procure fecal immunochemical tests, colorectal analyzers, immunochemical fecal occult blood testing services, fit testing instruments, and related supplies and reagents from Polymedco. The contracts, which do not have set-aside designations, are firm-fixed-price arrangements with a cumulative ceiling value over $350,000. The performance periods span multiple years, with the most recent awards covering April 2021 through March 2026. All contracted work will be conducted at Polymedco's facility in Cortlandt Manor, New York. These IDV awards allow the VA's Veterans Health Administration to standardize the procurement of critical cancer screening, diagnostic, and treatment equipment and services across its nationwide network of medical facilities.
Polymedco LLC
$352.1k 4/1/21 3/31/26 3/28/24 36F79720D0016-36C24825A0001
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) to Polymedco LLC, a for-profit organization doing business as Polymedco Cancer Diagnostic Products. The contract, valued up to $750,000.00, provides the VA's Veterans Health Administration with a multi-year vehicle to efficiently procure a range of cancer screening, diagnostic, and treatment-related products and services from Polymedco.
Specifically, the BPA enables the VA to issue task orders and BPA calls to Polymedco for automated immunochemical fecal occult blood tests, colorectal cancer analyzers, immunochemical fecal occult blood testing services, fit testing instruments, and associated supplies and reagents. These items are primarily utilized by VA medical facilities nationwide to support the agency's cancer screening, diagnosis, and treatment initiatives. The contract is a firm-fixed-price arrangement that leverages Polymedco's position on the General Services Administration's Federal Supply Schedule for Critical Analyzers, Laboratory, facilitating standardized, competitively awarded procurement of these products and services for the VA.
Polymedco LLC
$750.0k 10/1/24 9/30/25 10/1/24 36F79720D0016-36C24921A0004
The Department of Veterans Affairs Veterans Health Administration awarded a blanket purchase agreement to Polymedco LLC for fecal occult blood laboratory testing services across multiple Veterans Integrated Service Networks. The single award, firm-fixed price contract against Polymedco's Critical Analyzers, Laboratory GSA schedule has a potential value of $1,354,024.15 and period of performance from October 2020 through September 2025. The agreement facilitates colorectal cancer screening for veterans through task order calls by VISN 9 and VISN 12 valued at approximately $309,494.34, $512,005.28, $148,869.97, and $120,844.05 respectively, with testing to be performed by Polymedco at its Cortlandt Manor, New York location. The purpose of the contracted laboratory services is to support the healthcare mission of the VA by enabling facilities within the VISNs to efficiently order and receive fecal occult blood testing, which screens for signs of gastrointestinal cancers or other disorders, from a qualified provider.
The blanket purchase agreement was awarded on a single award basis using Polymedco's existing GSA Critical Analyzers, Laboratory schedule. No set-aside provisions were applied to the agreement or subsequent task order calls. Polymedco will deliver the contracted fecal occult blood laboratory testing from its New York location to multiple VA medical centers within VISN 9 and VISN 12 through September 2025. The agreement establishes an efficient means for the VA facilities to access these important cancer screening services while leveraging competitive pricing under Polymedco's established GSA schedule.
Polymedco LLC
$1.4m 10/1/20 9/30/25 9/28/23 36F79720D0016-36C25621A0026
The Department of Veterans Affairs (VA), through its Veterans Integrated Service Network (VISN) 16, has awarded a Blanket Purchase Agreement (BPA) to Polymedco LLC, a for-profit organization doing business as Polymedco Cancer Diagnostic Products. The BPA, valued at up to $1,861,957.88, is for the provision of automated fecal immunochemical occult blood testing equipment, supplies, and related services to support the VA's cancer screening and diagnostic initiatives across multiple VISN facilities.
The BPA is a single-award contract that leverages Polymedco's position on the General Services Administration's Federal Supply Schedule for Critical Analyzers, Laboratory. It does not have a set-aside designation, indicating full and open competition. Through this and other Indefinite Delivery Vehicles (IDVs), Polymedco has supplied the VA with a range of cancer screening, diagnostic, and treatment-related products and services, including fecal immunochemical tests, colorectal analyzers, and associated supplies and reagents. The majority of the contract's performance will take place at Polymedco's facility in Cortlandt Manor, New York, with an ultimate completion date of March 31, 2026.
Polymedco LLC
$1.9m 4/1/21 3/31/26 9/26/24